PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34349106-7 2021 Therapeutic cholesterol-lowering through simvastatin reduced systemic and neuro-inflammation, and the occurrence of memory deficits in aged ApoE-/- mice with chronic hypercholesterolemia. Simvastatin 41-52 apolipoprotein E Mus musculus 140-144 34422919-10 2021 Concomitant treatment of cholesterol-fed ApoE-/- mice with LT, the specific synthetic Rac1 inhibitor NSC 23766 or simvastatin comparably reduced aortic Rac1 activity, NADPH oxidase activity, oxidative stress, endothelial dysfunction, atherosclerosis development, and macrophage infiltration. Simvastatin 114-125 apolipoprotein E Mus musculus 41-45 35618653-8 2022 TPTS/C/T realized targeted drug release to plaques and synergistic therapeutic effects of simvastatin and ticagrelor on atherosclerosis treatment in an ApoE-/- mouse model, resulting in excellent atherosclerosis therapeutic efficacy and a promising biosafety profile. Simvastatin 90-101 apolipoprotein E Mus musculus 152-156 31731717-6 2019 Additionally, after combined therapy with simvastatin and lunasin for four weeks, ApoE-/- mice had significantly lower PCSK9 and higher LDLR levels in hepatic tissues and remarkably reduced plasma concentrations of total cholesterol (TC) and LDL-C, as compared to each monotherapy. Simvastatin 42-53 apolipoprotein E Mus musculus 82-86 33864447-3 2021 METHODS: Apolipoprotein E knockout (ApoE-/-) mice were administered with simvastatin (20 mg/kg/day) for 8 weeks. Simvastatin 73-84 apolipoprotein E Mus musculus 9-25 31731717-7 2019 Conclusively, lunasin significantly improved the LDL-C lowering efficacy of simvastatin by counteracting simvastatin induced elevation of PCSK9 in hepatocytes and ApoE-/- mice. Simvastatin 76-87 apolipoprotein E Mus musculus 163-167 30713570-9 2019 Conclusively, lipid-regulating and anti-inflammatory functions mediated by YQHP with lower hepatotoxicity than simvastatin hindered the progression of HSP65 aggravated AS in ApoE-/- mice, indicating the effectiveness of Yangyin Qingre Huoxue Method in the treatment of AS. Simvastatin 111-122 apolipoprotein E Mus musculus 174-178 29735887-10 2018 In ApoE-/- mice fed with an atherogenic diet, both UA (100 mg/kg/day) and simvastatin significantly attenuated atherosclerotic plaque formation and shrunk necrotic core areas. Simvastatin 74-85 apolipoprotein E Mus musculus 3-7 27091343-10 2016 Moreover, in vivo, ADMA administration reduced Matrigel plug angiogenesis in wild-type mice and decreased simvastatin-induced eNOS phosphorylation in aortas of apolipoprotein E-deficient mice, but not endothelial DDAH-2-overexpressed aortas. Simvastatin 106-117 apolipoprotein E Mus musculus 160-176 26295063-5 2015 To test this hypothesis, we used nanoparticle-based delivery of simvastatin to inhibit plaque macrophage proliferation in apolipoprotein E deficient mice (Apoe-/- ) with advanced atherosclerotic plaques. Simvastatin 64-75 apolipoprotein E Mus musculus 122-138 26295063-5 2015 To test this hypothesis, we used nanoparticle-based delivery of simvastatin to inhibit plaque macrophage proliferation in apolipoprotein E deficient mice (Apoe-/- ) with advanced atherosclerotic plaques. Simvastatin 64-75 apolipoprotein E Mus musculus 155-162 24998652-5 2014 Compared with ApoE-/- group, simvastatin significantly decreased atherosclerotic lesion area in aortic root (89 818.05+-16 980.93 mum2 vs 34 937.01+-13 280.65 mum2, P<0.05). Simvastatin 29-40 apolipoprotein E Mus musculus 14-18 24998652-12 2014 CONCLUSION: Simvastatin can attenuate atherosclerosis of aorta in ApoE-/- mice, which is associated with the reduced central aortic systolic pressure but not with the serum lipids levels. Simvastatin 12-23 apolipoprotein E Mus musculus 66-70 23216643-0 2012 Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in ApoE-deficient mice. Simvastatin 48-59 apolipoprotein E Mus musculus 98-102 23564080-0 2013 Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis. Simvastatin 0-11 apolipoprotein E Mus musculus 68-72 23564080-11 2013 Administration with simvastatin in ApoE(-/-) mice markedly attenuated the vascular inflammation and atherosclerotic lesion area, and decreased the aortic expression of HMGB1, RAGE, VCAM-1, and MCP-1. Simvastatin 20-31 apolipoprotein E Mus musculus 35-39 23564080-14 2013 CONCLUSION: Simvastatin inhibits vascular inflammation and atherosclerosis in ApoE(-/-) mice, which may be mediated through downregulation of the HMGB1-RAGE axis. Simvastatin 12-23 apolipoprotein E Mus musculus 78-82 24080182-7 2013 In apolipoprotein E-deficient mice, simvastatin and the inhibitors of p38 and ERK1/2 significantly increased the stability of the carotid plaques. Simvastatin 36-47 apolipoprotein E Mus musculus 3-19 23216643-10 2012 CONCLUSION: The combination of simvastatin and pinocembrin synergistically inhibited atherosclerotic lesion development in ApoE-/- mice with hyperlipidemia, which is partially dependent on the protective of vascular endothelium. Simvastatin 31-42 apolipoprotein E Mus musculus 123-127 22038096-9 2012 CONCLUSION: In the present study, we show novel data to suggest that simvastatin could suppress apoptosis in vulnerable atherosclerotic plaques of apoE(-/-) mice by regulating the expression of apoptosis-related proteins, such as p(53), Bcl-2 and Bcl-xL. Simvastatin 69-80 apolipoprotein E Mus musculus 147-151 22977450-0 2012 Simvastatin and losartan differentially and synergistically inhibit atherosclerosis in apolipoprotein e(-/-) mice. Simvastatin 0-11 apolipoprotein E Mus musculus 87-103 22038096-6 2012 Analysis of plaque composition showed that simvastatin decreased the area of lipid core and increased the amounts of macrophages and smooth muscle cells in atherosclerotic plaques of apoE(-/-) mice. Simvastatin 43-54 apolipoprotein E Mus musculus 183-187 21241519-0 2011 Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet. Simvastatin 0-11 apolipoprotein E Mus musculus 128-132 21241519-4 2011 RESULTS: The atherosclerotic lesion formation displayed by oil red O staining positive area was reduced significantly by 35% or 47% in either aortic root section or aortic arch en face in simvastatin administrated apoE-/- mice compared to the control. Simvastatin 188-199 apolipoprotein E Mus musculus 214-218 21241519-8 2011 CONCLUSIONS: We demonstrated the anti-atherogenesis effects of simvastatin in apoE-/- mice fed a high-fat diet. Simvastatin 63-74 apolipoprotein E Mus musculus 78-82 19639539-8 2010 And the plasma levels of cholesterol (Chol), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and ApoE all decreased in both the rhein and the simvastatin groups. Simvastatin 157-168 apolipoprotein E Mus musculus 112-116 20809215-8 2010 RESULTS: In ApoE(-/-) mice suprarenal aortic diameters were modestly smaller in animals receiving simvastatin without significant change despite reduction in macrophage infiltration. Simvastatin 98-109 apolipoprotein E Mus musculus 12-16 19729613-9 2009 CONCLUSIONS: These data support the conclusion that simvastatin interferes with AAA formation induced by AngII in ApoE(-/-) mice at least in part via ERK inhibition. Simvastatin 52-63 apolipoprotein E Mus musculus 114-118 19729613-0 2009 Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Simvastatin 0-11 apolipoprotein E Mus musculus 83-99 19738398-7 2009 Compared to ApoE-KO mice fed only the atherosclerotic diet, ApoE-KO mice treated with simvastatin had no significant hearing loss and less severe atherosclerosis and hair cell damage in the inner ear. Simvastatin 86-97 apolipoprotein E Mus musculus 60-64 15639308-7 2005 Simvastatin paradoxically increased lipid and atherosclerosis in apoE-KO mice, but it decreased lipid and atherosclerosis in LDLR-KO mice, indicating that anti-atherosclerotic effect of simvastatin requires the presence of an intact apoE. Simvastatin 0-11 apolipoprotein E Mus musculus 65-69 18443364-0 2008 Diabetes reduces aortic endothelial gap junctions in ApoE-deficient mice: simvastatin exacerbates the reduction. Simvastatin 74-85 apolipoprotein E Mus musculus 53-57 18295249-9 2008 The beneficial effect of simvastatin on uremia enhanced vascular calcification in apoE(-/-) mice with chronic kidney disease was observed despite the absence of changes in uremia accelerated atherosclerosis progression, serum total cholesterol levels or osteopontin and alkaline phosphatase expression. Simvastatin 25-36 apolipoprotein E Mus musculus 82-86 19578502-4 2008 RESULTS: ApoE-/- mice were treated with an ACE inhibitor ramipril and HMG-CoA reductase inhibitor simvastatin. Simvastatin 98-109 apolipoprotein E Mus musculus 9-13 17214935-10 2007 CONCLUSION: WQBP and simvastatin can interfere in early atherosclerosis of ApoE-mice, attenuate and stabilize plaque in some extent. Simvastatin 21-32 apolipoprotein E Mus musculus 75-79 16920939-5 2006 Serum cholesterol levels were unaffected by simvastatin treatment, but atherosclerotic lesion area was reduced in both apoE-/- and gld.apoE-/- mice treated with simvastatin. Simvastatin 161-172 apolipoprotein E Mus musculus 119-123 16920939-5 2006 Serum cholesterol levels were unaffected by simvastatin treatment, but atherosclerotic lesion area was reduced in both apoE-/- and gld.apoE-/- mice treated with simvastatin. Simvastatin 161-172 apolipoprotein E Mus musculus 135-139 16920939-6 2006 Simvastatin also reduced the lymphadenopathy, renal disease, and proinflammatory cytokine production seen in gld.apoE-/-, but not gld, mice. Simvastatin 0-11 apolipoprotein E Mus musculus 113-117 16460674-0 2006 Simvastatin causes the formation of cholesterol-rich remnants in mice lacking apoE. Simvastatin 0-11 apolipoprotein E Mus musculus 78-82 16460674-4 2006 ApoE-deficient mice fed a chow diet containing simvastatin developed, as anticipated, an enhanced increase in plasma cholesterol and a decrease in plasma triglycerides. Simvastatin 47-58 apolipoprotein E Mus musculus 0-4 16460674-8 2006 These results indicate that the enhanced hypercholesterolemia observed in apoE-deficient mice treated with simvastatin is not the result of an increased number of remnant particles in circulation but is caused by synthesis and secretion into the plasma of lipoproteins that are enriched in cholesterol and depleted of triglycerides. Simvastatin 107-118 apolipoprotein E Mus musculus 74-78 15572054-7 2004 Intramyocardial VEGF gene transfer increased capillary and arteriolar densities in the ApoE(-/-) mice, and simvastatin treatment further enhanced capillary density (P < 0.03) to a level similar to that of normal mice. Simvastatin 107-118 apolipoprotein E Mus musculus 87-91 15572054-8 2004 Simvastatin did not change the lipid profile but blocked p38 MAPK phosphorylation in the ApoE(-/-) myocardium. Simvastatin 0-11 apolipoprotein E Mus musculus 89-93 15572054-10 2004 Thus, increased myocardial angiogenesis in the ApoE(-/-) mice following transient overexpression of VEGF is further increased by additional simvastatin treatment. Simvastatin 140-151 apolipoprotein E Mus musculus 47-51 15300198-12 2004 The increase in eNOS induced by RAPA and the inverse relationship between p-eNOS and Cav-1 protein expression observed with SMV treatment suggest different mechanisms for the regulation of aortic eNOS expression in Apo-E mice by these 2 agents. Simvastatin 124-127 apolipoprotein E Mus musculus 215-220 14752252-7 2004 In apoE(-/- )mice, simvastatin caused a paradoxical increase in plasma cholesterol (1094 +/- 60.3 vs. 658 +/- 66.8 mg/dl; p < 0.001), confirmed by FPLC. Simvastatin 19-30 apolipoprotein E Mus musculus 3-7 14752252-12 2004 simvastatin treatment of apoE(-/-) mice caused paradoxical hyperlipidemia and increased intimal hyperplasia. Simvastatin 0-11 apolipoprotein E Mus musculus 25-29 12426212-0 2002 Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Simvastatin 0-11 apolipoprotein E Mus musculus 57-61 12426212-2 2002 METHODS AND RESULTS: Simvastatin (50 mg/kg per day) was administered to 30-week-old apolipoprotein E-deficient mice exhibiting advanced unstable atherosclerotic lesions within the innominate/brachiocephalic artery. Simvastatin 21-32 apolipoprotein E Mus musculus 84-100 11947894-0 2002 Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Simvastatin 31-42 apolipoprotein E Mus musculus 70-86 11947894-7 2002 These results suggest that the therapeutic effects of simvastatin may depend on the presence of a functional apolipoprotein E. Simvastatin 54-65 apolipoprotein E Mus musculus 109-125 11382730-0 2001 Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Simvastatin 0-11 apolipoprotein E Mus musculus 74-90 11382730-6 2001 However, the increased leukocyte rolling and adherence that occurred in cholesterol-fed apoE(-/-) mice (P<0.001 versus control diet) were significantly attenuated by simvastatin treatment (P<0.01 versus vehicle). Simvastatin 169-180 apolipoprotein E Mus musculus 88-92 11382730-8 2001 Simvastatin therapy also significantly increased vascular nitric oxide production in apoE(-/-) mice. Simvastatin 0-11 apolipoprotein E Mus musculus 85-89 12818400-0 2003 Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Simvastatin 0-11 apolipoprotein E Mus musculus 88-104 12818400-9 2003 In conclusion, these data suggest that chronic administration of simvastatin to older apo E-/- mice can inhibit the expression of pro-thrombotic/pro-inflammatory genes within established atherosclerotic lesions via mechanisms that are independent of reductions in plasma lipids. Simvastatin 65-76 apolipoprotein E Mus musculus 86-91